[
  {
    "ts": "2026-02-10T00:30:00+00:00",
    "headline": "Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens[1] for Astigmatic Adults living with Presbyopia",
    "summary": "Today, Johnson & Johnson announced the launch of two new contact lenses in Singapore – ACUVUE® OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM – the first and only daily disposable multifocal toric contact lens for people with both astigmatism and presbyopia,[1] and ACUVUE® OASYS MAX 1-Day for ASTIGMATISM. Designed to address the evolving needs of astigmatic patients, both lenses provide exceptional comfort, clarity and stability,[+],[**],[2],[3] plus crisp, clear vision at all distances and in all l",
    "url": "https://finance.yahoo.com/news/johnson-johnson-launches-first-only-003000485.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "c22eda00-c748-3495-a6c4-2fae0fb2ef3e",
      "content": {
        "id": "c22eda00-c748-3495-a6c4-2fae0fb2ef3e",
        "contentType": "STORY",
        "title": "Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens[1] for Astigmatic Adults living with Presbyopia",
        "description": "",
        "summary": "Today, Johnson & Johnson announced the launch of two new contact lenses in Singapore – ACUVUE® OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM – the first and only daily disposable multifocal toric contact lens for people with both astigmatism and presbyopia,[1] and ACUVUE® OASYS MAX 1-Day for ASTIGMATISM. Designed to address the evolving needs of astigmatic patients, both lenses provide exceptional comfort, clarity and stability,[+],[**],[2],[3] plus crisp, clear vision at all distances and in all l",
        "pubDate": "2026-02-10T00:30:00Z",
        "displayTime": "2026-02-10T00:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/69c6b64bb2bb88dcb0943d1efbea3054",
          "originalWidth": 400,
          "originalHeight": 37,
          "caption": "Johnson & Johnson logo (PRNewsfoto/Johnson & Johnson)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QH2dFsQ9Hz2iJanf7Rh._Q--~B/aD0zNzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/69c6b64bb2bb88dcb0943d1efbea3054.cf.webp",
              "width": 400,
              "height": 37,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ksTJ99k4dB3NfNRyqXUbYg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/69c6b64bb2bb88dcb0943d1efbea3054.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-launches-first-only-003000485.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-launches-first-only-003000485.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T03:13:09+00:00",
    "headline": "Johnson & Johnson Highlights Pipeline Breadth Across Cardiology, Oncology And Vision Care",
    "summary": "Johnson & Johnson (NYSE:JNJ) reports strong 12 month pilot-phase data for its OMNYPULSE platform in atrial fibrillation treatment. The company shares expanded safety data for its VARIPULSE platform, also focused on atrial fibrillation care. Johnson & Johnson launches new daily disposable multifocal toric contact lenses within its ACUVUE product line. New real world evidence highlights ERLEADA as a leading therapy option for metastatic castration sensitive prostate cancer. For a healthcare...",
    "url": "https://finance.yahoo.com/news/johnson-johnson-highlights-pipeline-breadth-031309194.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "2c6f2458-5e3e-3432-80b4-001c2fe4f5a0",
      "content": {
        "id": "2c6f2458-5e3e-3432-80b4-001c2fe4f5a0",
        "contentType": "STORY",
        "title": "Johnson & Johnson Highlights Pipeline Breadth Across Cardiology, Oncology And Vision Care",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) reports strong 12 month pilot-phase data for its OMNYPULSE platform in atrial fibrillation treatment. The company shares expanded safety data for its VARIPULSE platform, also focused on atrial fibrillation care. Johnson & Johnson launches new daily disposable multifocal toric contact lenses within its ACUVUE product line. New real world evidence highlights ERLEADA as a leading therapy option for metastatic castration sensitive prostate cancer. For a healthcare...",
        "pubDate": "2026-02-10T03:13:09Z",
        "displayTime": "2026-02-10T03:13:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VmOStVnJjLnU3xikg4stLA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/trESudVvS0UypUeXuQ_Yww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-highlights-pipeline-breadth-031309194.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-highlights-pipeline-breadth-031309194.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T11:41:51+00:00",
    "headline": "Where is Genmab A/S (GMAB) Headed According to Wall Street?",
    "summary": "Genmab A/S (NASDAQ:GMAB) is one of the best healthcare stocks under $50 to invest in. Genmab A/S (NASDAQ:GMAB) announced on January 21 that the worldwide net trade sales of DARZALEX, including sales of the subcutaneous product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J, came up to $14.351 billion […]",
    "url": "https://finance.yahoo.com/news/where-genmab-gmab-headed-according-114151220.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "404a837d-867c-394b-acd7-d6c1b2c738cf",
      "content": {
        "id": "404a837d-867c-394b-acd7-d6c1b2c738cf",
        "contentType": "STORY",
        "title": "Where is Genmab A/S (GMAB) Headed According to Wall Street?",
        "description": "",
        "summary": "Genmab A/S (NASDAQ:GMAB) is one of the best healthcare stocks under $50 to invest in. Genmab A/S (NASDAQ:GMAB) announced on January 21 that the worldwide net trade sales of DARZALEX, including sales of the subcutaneous product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J, came up to $14.351 billion […]",
        "pubDate": "2026-02-10T11:41:51Z",
        "displayTime": "2026-02-10T11:41:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/92ad993b23d1981cda76510cabc277ab",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now?",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/V1OWmCXiS8LnmGn5E4BtEQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/92ad993b23d1981cda76510cabc277ab.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FWwGn7BFzbQphqwsKW5kbw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/92ad993b23d1981cda76510cabc277ab.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/where-genmab-gmab-headed-according-114151220.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/where-genmab-gmab-headed-according-114151220.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GMAB"
            },
            {
              "symbol": "GNMSF"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T13:32:00+00:00",
    "headline": "Here's What Will Drive AbbVie's Top-line Growth in 2026",
    "summary": "ABBV sees 2026 revenues rising to $67B as Rinvoq and Skyrizi drive growth, with neuroscience gains offsetting Humira erosion and oncology headwinds.",
    "url": "https://finance.yahoo.com/news/heres-drive-abbvies-top-line-133200185.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "d5ce5f2c-6f21-3316-a124-99ee64b1d098",
      "content": {
        "id": "d5ce5f2c-6f21-3316-a124-99ee64b1d098",
        "contentType": "STORY",
        "title": "Here's What Will Drive AbbVie's Top-line Growth in 2026",
        "description": "",
        "summary": "ABBV sees 2026 revenues rising to $67B as Rinvoq and Skyrizi drive growth, with neuroscience gains offsetting Humira erosion and oncology headwinds.",
        "pubDate": "2026-02-10T13:32:00Z",
        "displayTime": "2026-02-10T13:32:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OQG3.5Wd9P9R69q2rhm9rA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pBlncPVBhEXpjxtBDlEOsg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-drive-abbvies-top-line-133200185.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-drive-abbvies-top-line-133200185.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "RHHBY"
            },
            {
              "symbol": "RHHVF"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T10:53:50+00:00",
    "headline": "4 takeaways from the 2026 AF Symposium",
    "summary": "Johnson & Johnson, Boston Scientific and Abbott were among the companies showcasing new data on atrial fibrillation treatments, including pulsed field ablation catheters.",
    "url": "https://www.medtechdive.com/news/4-takeaways-2026-AF-Symposium-AFib-PFA-Boston/811825/",
    "source": "MedTech Dive",
    "provider": "yfinance",
    "raw": {
      "id": "51c7ef9b-1889-3c66-8007-ff5fb3dc7b5d",
      "content": {
        "id": "51c7ef9b-1889-3c66-8007-ff5fb3dc7b5d",
        "contentType": "STORY",
        "title": "4 takeaways from the 2026 AF Symposium",
        "description": "",
        "summary": "Johnson & Johnson, Boston Scientific and Abbott were among the companies showcasing new data on atrial fibrillation treatments, including pulsed field ablation catheters.",
        "pubDate": "2026-02-10T10:53:50Z",
        "displayTime": "2026-02-10T10:53:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/medtech_dive_335/f99a0bd2c5e2b86831da56f48dc36599",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/azEZbt5vHOXVbB_.HBR8MQ--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/medtech_dive_335/f99a0bd2c5e2b86831da56f48dc36599.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hbnHfZDRvdq9oH9IO0EI7A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/medtech_dive_335/f99a0bd2c5e2b86831da56f48dc36599.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MedTech Dive",
          "url": "https://medtechdive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.medtechdive.com/news/4-takeaways-2026-AF-Symposium-AFib-PFA-Boston/811825/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/4-takeaways-2026-af-symposium-105350144.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "ABT"
            },
            {
              "symbol": "BSX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-10T21:51:00+00:00",
    "headline": "Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway.",
    "summary": "Less than two months into 2026, shares of  Gilead Sciences  are already outpacing some of the most talked-about pharmaceutical companies.  After the closing bell, the biopharmaceutical company posted adjusted earnings of $1.86 a share, which outstripped analysts’ calls for $1.81.  Gilead attributed the change to higher sales of HIV and liver-disease products, which were partially offset by lower sales of Veklury, its Covid-19 antiviral.",
    "url": "https://www.barrons.com/articles/gilead-earnings-stock-price-f1f36bf5?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "8a748589-aea8-3e07-a0d3-cb4d585b2ae3",
      "content": {
        "id": "8a748589-aea8-3e07-a0d3-cb4d585b2ae3",
        "contentType": "STORY",
        "title": "Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway.",
        "description": "",
        "summary": "Less than two months into 2026, shares of  Gilead Sciences  are already outpacing some of the most talked-about pharmaceutical companies.  After the closing bell, the biopharmaceutical company posted adjusted earnings of $1.86 a share, which outstripped analysts’ calls for $1.81.  Gilead attributed the change to higher sales of HIV and liver-disease products, which were partially offset by lower sales of Veklury, its Covid-19 antiviral.",
        "pubDate": "2026-02-10T21:51:00Z",
        "displayTime": "2026-02-10T21:51:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/8a748589-aea8-3e07-a0d3-cb4d585b2ae3/gilead-earnings-surprise-why.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/89f489d64b0a92a4a22fd03aa27f2b15",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/X078vvJXUIiLEBq8utnocA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/89f489d64b0a92a4a22fd03aa27f2b15.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cpMrX8Jl6P9ldyk1tq3_og--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/89f489d64b0a92a4a22fd03aa27f2b15.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/gilead-earnings-stock-price-f1f36bf5?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]